Ospedale Santa Maria Goretti Latina
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Ospedale Santa Maria Goretti Latina the cardiology unit is testing innovative approaches to improve outcomes after acute myocardial infarction, including strategies to protect coronary microcirculation and to limit atherosclerotic progression.
- Evaluation of late sodium current inhibition to preserve microvascular function after STEMI
- Impact of SGLT2 inhibitors on coronary plaque stability post‑PCI
- Optimizing proteinuria management in patients with cardiovascular‑renal overlap
- Comparative effectiveness of novel antithrombotic regimens in multivessel disease
The department currently runs 15 trials with 12 investigators, positioning the site as a hub for cardiovascular innovation in Italy.
Hemic and Lymphatic Diseases
Research at the hospital focuses on personalized therapies for blood‑related malignancies such as acute myeloid leukemia with FLT3 mutations and chronic myeloid leukemia in chronic phase, aiming to enhance survival while reducing treatment toxicity.
- Biomarker‑guided intensification for FLT3‑positive AML
- Front‑line nilotinib versus imatinib strategies in CML
- Combination immunotherapy for relapsed marginal zone lymphoma
- Assessment of gemtuzumab ozogamicin in AML consolidation
With a portfolio of hematology trials, the unit contributes to advancing care for patients across Europe.
Immune System Diseases
The site investigates immune‑modulating treatments for conditions like IgA nephropathy and Hodgkin’s lymphoma, exploring ways to balance efficacy and safety in chronic disease management.
- Early corticosteroid therapy versus RAS blockade in IgAN
- SGLT2 inhibitor regimens to reduce proteinuria in renal disease
- Phase I/II study of atezolizumab combined with BEGEV for relapsed Hodgkin’s lymphoma
- Evaluation of novel checkpoint inhibitors in refractory lymphomas
The immunology program includes 15 active studies, supported by a multidisciplinary team of 12 investigators.
Neoplasms
Oncology trials at the facility target solid and hematologic tumors, including breast cancer and acute lymphoblastic leukemia, to refine treatment sequencing and improve long‑term remission rates.
- Sequential versus concurrent chemotherapy and aromatase inhibitors in early breast cancer
- Chemo‑free Ponatinib and Blinatumomab regimen for Ph+ ALL
- MRD‑driven strategies for remission in ALL and AML
- Combination therapies to enhance progression‑free survival in marginal zone lymphoma
The cancer research program leverages 15 clinical investigations, fostering collaboration across European oncology networks.
Nutritional and Metabolic Diseases
Studies in metabolic health aim to assess the benefits of newer agents such as semaglutide and SGLT2 inhibitors for patients with type 2 diabetes mellitus, focusing on glycemic control and cardiovascular risk reduction.
- Non‑inferiority of semaglutide added to reduced‑dose insulin versus intensified insulin therapy
- Achievement of individualized HbA1c targets with different SGLT2i compounds
- Effect of SGLT2i on coronary atherosclerosis progression after myocardial infarction
- Safety and efficacy of glucagon‑like peptide‑1 receptor agonists in overweight diabetic patients
The metabolic research unit conducts 15 trials, contributing valuable data to global diabetes treatment guidelines.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 59 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale Santa Maria Goretti Latina
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | Jun 2026 |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 5 | Unknown | 2020-04-24 | 2021-09-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.